Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the Forefront | DelveInsight
Approximately 10% of women of reproductive age worldwide are affected by endometriosis, equating to about 190 million individuals. This substantial patient population necessitates effective treatments, propelling market demand this increasing disease prevalence is driving the market for endometriosis.
LAS VEGAS, Jan. 29, 2025 /PRNewswire/ -- DelveInsight's 'Endometriosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline endometriosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the endometriosis pipeline domain.
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
Key Takeaways from the Endometriosis Pipeline Report
-- DelveInsight's endometriosis pipeline report depicts a robust space with
15+ active players working to develop 20+ pipeline therapies for
endometriosis treatment.
-- Key endometriosis companies such as Kissei Pharmaceutical, Mithra
Pharmaceuticals, Gesynta Pharma, Jiangsu Hengrui Medicine Co., Ferring
Pharmaceuticals, Hope Medicine (Nanjing) Co., Ltd, VaRi Bioscience, SWK
Holdings, Ananda Developments, TiumBio, Ironwood Pharmaceuticals, Chugai
Pharmaceutical, Viramal, Organon, Mitsubishi Tanabe Pharma, Antev,
Foraviset, ValiRx, EpicentRx, Temple Therapeutics, Celmatix, BCI Pharma,
Gynica, PrecisionLife, Flightpath Biosciences, and others are evaluating
new endometriosis drugs to improve the treatment landscape.
-- Promising endometriosis pipeline therapies such as Linzagolix, Estelle,
Vipoglanstat, SHR7280, Quinagolide, HMI-115, VR103, Ovarest, MRX1,
TU2670, IW-3300, AMY-109, VML 0501, OG-6219, Teverelix trifluoroacetate,
Raviset, VAL301, Nibrozetone, TTX334e, IntraVagS302, IntraVagS301,
FP-300, and others are under different phases of endometriosis clinical
trials.
-- In October 2024, Lisata Therapeutics, Inc. announced that it has entered
into a sponsored research agreement with the University of Cincinnati to
investigate Lisata's novel cyclic peptide product candidate,
certepetide, in combination with bevacizumab (a VEGF inhibitor) in a
preclinical animal model for the treatment of endometriosis.
-- In October 2024, Hope Medicine Inc. announced positive results from an
interim analysis of a global Phase II study, " A Randomized,
Multicenter, Double-Blind, Placebo -Controlled Phase 2 Study to Evaluate
the Safety and Efficacy of HMI-115 in Women with Moderate to Severe
Endometriosis Associated Pain Over a 12-Week Treatment Period". HMI-115
is a monoclonal antibody that blocks the prolactin receptor. It is a
first-in-class treatment for endometriosis. Notably, HMI-115 has been
granted Breakthrough Therapy Designation by the National Medical
Products Administration ("NMPA") in China.
-- In May 2024, Neurocrine Biosciences, Inc. announced the initiation of
its Phase I first-in-human clinical study to evaluate the safety,
tolerability, pharmacokinetics, and pharmacodynamics of investigational
compound NBI-1117567 in healthy adult participants. NBI-1117567 is an
investigational, oral, M1/M4 (M1 preferring) selective muscarinic
agonist for the potential treatment of neurological and neuropsychiatric
conditions.
-- In May 2024, TiumBio Co., Ltd. focused on discovering and developing
innovative therapeutics for patients with rare and incurable diseases,
announced positive topline results from its Phase 2a clinical trial of
Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor
antagonist, in patients with moderate to severe endometriosis-associated
pain.
Request a sample and discover the recent advances in endometriosis treatment drugs @ Endometriosis Pipeline Report
The endometriosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage endometriosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the endometriosis clinical trial landscape.
Endometriosis Overview
Endometriosis is a condition where tissue similar to the endometrium, which lines the uterus, grows outside of it. This often occurs in the lower abdomen or pelvic region but can occasionally be found elsewhere in the body. It commonly causes pelvic pain and may lead to infertility. The condition can begin with a person's first menstrual cycle and persist until menopause. The exact cause of endometriosis remains unknown, and there is currently no way to prevent it.
While there is no cure, symptoms can be managed through medications or, in some cases, surgery. Not all individuals with endometriosis experience symptoms, but common ones include pelvic pain, painful periods, discomfort during sexual intercourse, and challenges with conception. Approximately 10% of women of reproductive age are affected, though the true prevalence is difficult to determine as diagnosis often requires laparoscopic surgery to confirm the presence of lesions.
Endometriosis is a complex and widespread condition affecting women worldwide, regardless of ethnicity or social status. It is believed to result from multiple factors, including retrograde menstruation and cellular metaplasia, where cells outside the uterus transform into endometrial-like tissue. The condition is also heavily influenced by estrogen, which promotes inflammation, growth, and pain associated with the disease.
Diagnosing endometriosis typically involves assessing a patient's menstrual and pelvic pain history. Although various diagnostic tools have been proposed, none are fully validated to identify individuals with certainty. Symptoms can mimic other conditions, leading to diagnostic delays. Imaging techniques like ultrasonography or MRI may be used to detect ovarian endometriomas, adhesions, or deep nodular lesions. Histologic confirmation, often following laparoscopic visualization, helps confirm the diagnosis but should not delay the initiation of empirical medical treatment.
Treatment options range from conservative approaches, such as non-steroidal anti-inflammatory drugs (e.g., ibuprofen) to manage pain, to hormone-based medications that help control symptoms. Surgical intervention can both diagnose and treat endometriosis, with procedures to remove or destroy lesions and scar tissue, potentially alleviating pain and restoring normal pelvic anatomy.
Find out more about endometriosis treatment drugs @ Drugs for Endometriosis Treatment
A snapshot of the Endometriosis Pipeline Drugs mentioned in the report:
Drugs Company Phase
MoA RoA
Linzagolix Kissei Pharmaceutical Phase
III
LHRH receptor antagonists
Oral
Estelle Mithra Pharmaceuticals Phase Estrogen receptor agonists; Hormone replacements; Mineralocorticoid receptor antagonists;
III Progesterone receptor agonists; Testosterone congener inhibitors
NA
Vipoglanstat
Gesynta Pharma Phase II
Prostaglandin-E synthase inhibitors
Oral
SHR7280 Jiangsu Hengrui
Medicine Co. Phase II
Gonadotropin-releasing hormone inhibitors
Oral
Quinagolide Ferring Pharmaceuticals Phase II
Dopamine D2 receptor agonists Vaginal delivery
HMI-115 Hope Medicine (Nanjing)
Co., Ltd Phase II
Prolactin receptor antagonists Subcutaneous
VR103 VaRi Bioscience Phase II
Progesterone receptor agonists Vaginal,
Controlled-
release
Teverelix trifluoroacetate
Antev Phase I
Gonadotropin-releasing hormone inhibitors
NA
Learn more about the emerging endometriosis pipeline therapies @ Endometriosis Clinical Trials
Endometriosis Therapeutics Assessment
The endometriosis pipeline report proffers an integral view of the endometriosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Endometriosis Pipeline Report
-- Coverage: Global
-- Therapeutic Assessment By Product Type: Mono, Combination,
Mono/Combination
-- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical,
Phase I, Phase II, Phase III
-- Therapeutics Assessment By Route of Administration: Oral, Intravenous,
Subcutaneous, Parenteral, Topical
-- Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides,
Polymer, Small molecule, Gene therapy
-- Therapeutics Assessment By Mechanism of Action: LHRH receptor
antagonists, Estrogen receptor agonists, Hormone replacements,
Mineralocorticoid receptor antagonists, Progesterone receptor agonists,
Testosterone congener inhibitors, Prostaglandin-E synthase inhibitors,
Gonadotropin-releasing hormone inhibitors, Dopamine D2 receptor
agonists, Prolactin receptor antagonists,
-- Key Endometriosis Companies: Kissei Pharmaceutical, Mithra
Pharmaceuticals, Gesynta Pharma, Jiangsu Hengrui Medicine Co., Ferring
Pharmaceuticals, Hope Medicine (Nanjing) Co., Ltd, VaRi Bioscience, SWK
Holdings, Ananda Developments, TiumBio, Ironwood Pharmaceuticals, Chugai
Pharmaceutical, Viramal, Organon, Mitsubishi Tanabe Pharma, Antev,
Foraviset, ValiRx, EpicentRx, Temple Therapeutics, Celmatix, BCI Pharma,
Gynica, PrecisionLife, Flightpath Biosciences, and others.
-- Key Endometriosis Pipeline Therapies: Linzagolix, Estelle, Vipoglanstat,
SHR7280, Quinagolide, HMI-115, VR103, Ovarest, MRX1, TU2670, IW-3300,
AMY-109, VML 0501, OG-6219, Teverelix trifluoroacetate, Raviset, VAL301,
Nibrozetone, TTX334e, IntraVagS302, IntraVagS301, FP-300 and others.
Dive deep into rich insights for new drugs for endometriosis treatment, visit @ Endometriosis Drugs
Table of Contents
1.
Endometriosis Pipeline Report Introduction
2. Endometriosis Pipeline Report Executive Summary
3.
Endometriosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5.
Endometriosis Clinical Trial Therapeutics
6. Endometriosis Pipeline: Late-Stage Products (Pre-
registration)
7. Endometriosis Pipeline: Late-Stage Products (Phase
III)
8. Endometriosis Pipeline: Mid-Stage Products (Phase II)
9. Endometriosis Pipeline: Early-Stage Products (Phase
I)
10. Endometriosis Pipeline Therapeutics Assessment
11. Inactive Products in the Endometriosis Pipeline
12. Company-University Collaborations (Licensing/
Partnering) Analysis
13.
Key Companies
14.
Key Products in the Endometriosis Pipeline
15.
Unmet Needs
16.
Market Drivers and Barriers
17.
Future Perspectives and Conclusion
18.
Analyst Views
19.
Appendix
For further information on the endometriosis pipeline therapeutics, reach out @ Endometriosis Treatment Drugs
Related Reports
Endometriosis Market Insights, Epidemiology, and Market Forecast - 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key endometriosis companies including AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others.
Endometriosis Epidemiology Forecast
Endometriosis Epidemiology Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted endometriosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Endometriosis Pain Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others.
Endometriosis Pain Pipeline Insight - 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/endometriosis-clinical-trial-pipeline-gains-momentum-as-15-key-companies-at-the-forefront--delveinsight-302362843.html
SOURCE DelveInsight Business Research, LLP
